Article
Biochemistry & Molecular Biology
Hiroyuki Arai, Andrew Elliott, Joshua Millstein, Joanne Xiu, Fang-Shu Ou, Federico Innocenti, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Davendra Sohal, Richard M. Goldberg, Michael J. Hall, Aaron J. Scott, Mohd Khushman, Jimmy J. Hwang, Emil Lou, Benjamin A. Weinberg, Albert Craig Lockhart, Anthony Frank Shields, Jim P. Abraham, Daniel Magee, Phillip Stafford, Jian Zhang, Alan P. Venook, W. Michael Korn, Heinz-Josef Lenz
Summary: Loss-of-function alterations in NF1 gene activate RAS, a driver of colorectal cancer. NF1-mutant tumors frequently also have mutations in PIK3CA and PTEN genes. Low NF1 expression may be associated with poor prognosis, while high expression may enhance the efficacy of cetuximab compared to bevacizumab. Further investigation in clinical settings is needed to explore the potential of NF1 alteration as a novel biomarker for targeted therapy.
Review
Pharmacology & Pharmacy
Zaina T. Al-Salama
Summary: Encorafenib in combination with cetuximab has shown significantly longer overall survival, higher response rate, and better tolerability in patients with mCRC and a BRAF V600E mutation who have had prior therapy.
Article
Oncology
Benny Vittrup Jensen, Jakob Schou, Mette Yilmaz, Helle H. Johannesen, Kristin Skougaard, Dorte Linnemann, Estrid Hogdall, Finn O. Larsen, Julia S. Johansen, Per Pfeiffer, Dorte L. Nielsen
Summary: This study investigated the use of cetuximab and irinotecan in third-line treatment for mCRC patients, regardless of RAS or BRAF mutation status, and achieved certain efficacy. Shortening the treatment time while maintaining good treatment outcomes.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Marcin Szemitko, Elzbieta Golubinska-Szemitko, Jerzy Sienko, Aleksander Falkowski, Ireneusz Wiernicki
Summary: The aim of this study was to investigate the efficacy of irinotecan-releasing beads in the treatment of metastatic colorectal cancer after prior cetuximab monotherapy. The study found no statistically significant difference in radiological response to treatment based on prior cetuximab therapy, but a significant correlation between low baseline CEA values and treatment response. Prior treatment with anti-EGFR antibodies did not significantly affect radiological response or post-treatment progression.
Review
Oncology
Matthew Fowler, Helene Tobback, Alice Karuri, Paz Fernandez-Ortega
Summary: Encorafenib, a BRAF inhibitor, in combination with cetuximab, an EGFR inhibitor, has been approved for the treatment of BRAF(V600E)-mutant metastatic colorectal cancer. Nurses play a crucial role in managing the care of these patients, including early identification and management of treatment-related adverse events, as well as educating patients and caregivers about these events.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Davide Brocco, Pasquale Simeone, Davide Buca, Pietro Di Marino, Michele De Tursi, Antonino Grassadonia, Laura De Lellis, Maria Teresa Martino, Serena Veschi, Manuela Iezzi, Simone De Fabritiis, Marco Marchisio, Sebastiano Miscia, Alessandro Cama, Paola Lanuti, Nicola Tinari
Summary: This study examined the prognostic and predictive value of blood circulating EVs in patients with mCRC. Increased concentrations of tumor-induced blood circulating EVs, specifically CD133+ EVs, were associated with poor clinical outcomes. These findings suggest that EVs may serve as potential biomarkers for risk stratification and treatment selection in mCRC.
Article
Oncology
Alessandro Ottaiano, Guglielmo Nasti, Mariachiara Santorsola, Vincenzo Altieri, Giuseppina Di Fruscio, Luisa Circelli, Amalia Luce, Alessia Maria Cossu, Giosue Scognamiglio, Francesco Perri, Marco Correra, Andrea Belli, Paolo Delrio, Gerardo Botti, Michele Caraglia
Summary: Our study demonstrates that the evolutionary trajectories of KRAS play a significant clinical prognostic role in CRC patients and can help differentiate between poly-metastatic aggressive and oligo-metastatic indolent CRC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yi-Chia Su, Chih-Chien Wu, Chien-Chou Su, Meng-Che Hsieh, Ching-Lan Cheng, Yea-Huei Kao Yang
Summary: This study assessed the effectiveness of bevacizumab and cetuximab therapies in patients with metastatic colorectal cancer who did not undergo primary tumor resection. The results showed that cetuximab-based therapy had significantly better survival and conversion surgery rates compared to bevacizumab-based therapy in these patients.
Article
Oncology
Catherine G. Tran, Paolo Goffredo, Sarah L. Mott, Mohammed O. Suraju, Julia F. Kohn, Aditi Mishra, Jean-Nicolas Vauthey, Imran Hassan
Summary: This study investigates the impact of laterality, microsatellite instability (MSI), and KRAS status on conditional overall survival (COS) in colon cancer. The results show that mKRAS is associated with worse COS, suggesting a more aggressive biological behavior.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Said A. Khelwatty, Soozana Puvanenthiran, Sharadah Essapen, Izhar Bagwan, Alan M. Seddon, Helmout Modjtahedi
Summary: The study revealed that high levels of HER2 expression were found in CRC patients treated with cetuximab, which was associated with shorter progression free survival. The results support the emergence of HER2 as a therapeutic target in mCRC patients.
Article
Pharmacology & Pharmacy
Meiqin Yuan, Zeng Wang, Yazhen Zhao, Tingting Feng, Wangxia Lv, Haijun Zhong
Summary: Maintenance therapy can significantly improve the survival of mCRC patients. Research indicates that cetuximab maintenance therapy may provide potential benefits in first-line treatment, although further evidence is needed.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Wambui Gathirua-Mwangi, Tony Yang, Taha Khan, Yixun Wu, Manuel Afable
Summary: This retrospective study examined the baseline characteristics, treatment duration, and real-world overall survival (rwOS) in patients with metastatic colorectal cancer receiving cetuximab as second-line (2L) or third-line (3L) treatment. The study found that the median treatment duration was 3.7 months and rwOS was 14.4 months in the 2L cohort, while in the 3L cohort, the treatment duration was 3.3 months and rwOS was 12.0 months. This study provides evidence of the real-world overall survival in patients receiving cetuximab-based regimens as 2L or 3L treatment for metastatic colorectal cancer.
Article
Oncology
Stefano Mariani, Marco Puzzoni, Riccardo Giampieri, Pina Ziranu, Valeria Pusceddu, Clelia Donisi, Mara Persano, Giovanna Pinna, Erika Cimbro, Alissa Parrino, Dario Spanu, Andrea Pretta, Eleonora Lai, Nicole Liscia, Alessio Lupi, Enrica Giglio, Grazia Palomba, Milena Casula, Marina Pisano, Giuseppe Palmieri, Mario Scartozzi
Summary: This study investigated the efficacy of liquid biopsy-driven cetuximab rechallenge in a selected population of CRC patients with RAS and BRAF WT. The results showed that liquid biopsy-driven cetuximab rechallenge was effective and consistent with previous phase II studies. In addition to molecular selection, a longer anti-EGFR free interval was confirmed as an important predictor for this therapeutic option.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
David Sefrioui, Ludivine Beaussire, Andre Gillibert, France Blanchard, Emmanuel Toure, Celine Bazille, Anne Perdrix, Frederic Ziegler, Alice Gangloff, Melanie Hassine, Caroline Elie, Anne-Laure Bignon, Aurelie Parzy, Philippe Gomez, Caroline Thill, Florian Clatot, Jean-Christophe Sabourin, Thierry Frebourg, Jacques Benichou, Karine Bouhier-Leporrier, Marie-Pierre Gallais, Nasrin Sarafan-Vasseur, Pierre Michel, Frederic Di Fiore
Summary: The study confirmed the importance of CEA kinetics in predicting PD, and found that a circulating scoring system combining CEA kinetics, baseline CA19-9, and cfDNA values was independently associated with PD, PFS, and OS in mCRC patients.
BRITISH JOURNAL OF CANCER
(2021)